What is the NeuroDeRisk consortium?

NeuroDeRisk is a public-private partnership with 18 partners from academia and industry.

What is the main goal of NeuroDeRisk?

NeuroDeRisk overarching goal is to provide novel validated integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system and thus help to de-risk drug candidates earlier in the R&D phases.

How is the NeuroDeRisk project addressing this task?
  • NeuroDeRisk will collect, organize and expand existing knowledge on adverse effects of pharmaceuticals related to seizures, psychological/psychiatric changes, and peripheral neuropathies
  • NeuroDeRisk will develop new and/or improve existing tools to better predict such effects at preclinical stages of the R&D process
  • NeuroDeRisk will favor innovative approaches that fulfil the 3Rs approach (“Reduce, Refine, Replace” animal use)
  • NeuroDeRisk will organize tools and associated data in a comprehensive and integrated toolbox to aid decision-making process in R&D projects, reduce attrition and increase productivity for innovative and safer pharmaceuticals.
Who is funding NeuroDeRisk?

NeuroDeRisk is funded by a grant from the Innovative Medicines Initiative (IMI). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Why is NeuroDeRisk aiming to reduce neurotoxicity?

Neurotoxicity, i.e., any adverse effect on the central nervous system (CNS) or peripheral nervous system (PNS), is a major issue encountered in clinical phases of drug Research & Development (R&D) that at the present stage of science and technology is still poorly predicted in pre-clinical drug candidate assessment, and therefore presents an unmet challenge in the quest for innovative and safe drugs.

How will NeuroDeRisk reduce neurotoxicity?

By combining the expertise of top level academic scientists, successful industrial software developers, and preclinical safety scientists from the pharmaceutical industry, NeuroDeRisk will provide novel validated integrated tools for improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system and thus help to de-risk drug candidates earlier in the R&D phases.

The collaboration within the NeuroDeRisk consortium will ensure both significant benefits for society by helping patients by delivering safer, better medicines, protecting human volunteers in clinical trials, and finally making the R&D process more efficient by helping industry with top level science to de-risk the discovery of new drugs with high unmet medical need, as still exist across all therapy areas.